TNT: Sub-analysis in CHD Patients with Diabetes & CKD

18 Aug, 10

TNT: Sub-analysis in CHD Patients with Diabetes & CKD

Introduction

Intensive Lipid Lowering with Atorvastatin is Associated with Significant Cardiovascular Benefits in CHD Patients With Type 2 Diabetes and CKD: Subanalysis of Treating to New Targets (TNT) study

To evaluate the effect of intensive lipid lowering with atorvastatin 80 mg on the incidence of major cardiovascular events compared with atorvastatin 10 mg in patients of stable coronary heart disease (CHD) with type 2 diabetes (T2DM) and chronic kidney disease (CKD)

Patients

Stable CHD with T2DM and estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m² at baseline (N=546)

Study Groups

Atorvastatin 80 mg vs. 10 mg

Median Follow-up Period

5 years

End-Point

Major cardiovascular event defined as a composite of CHD death, nonfatal, non-procedure-related myocardial infarction, resuscitated cardiac arrest, fatal or nonfatal stroke

Results

Compared with atorvastatin 10 mg, atorvastatin 80 mg reduced the relative risk of major cardiovascular events by 35% (Figure)

Figure. Impact on CV events with atorvastatin 80 mg vs. 10mg

The absolute risk reduction in major cardiovascular events with atorvastatin 80 mg vs. 10 mg was 7%
Both the treatments were well tolerated

Conclusion

Atorvastatin 80 mg as compared to atorvastatin 10 mg significantly reduces the incidence of major cardiovascular events in stable CHD patients with T2DM and CKD, without any safety concerns.

Presented at 67th Scientific Sessions of ADA, June 22-26, 2007. Presentation Title "Intensive Lipid Lowering With Atorvastatin is Associated With Significant Cardiovascular Benefits in Coronary Patients With Type 2 Diabetes and Chronic Kidney Disease: The TNT Study". Abstract number 0265-OR

Mayo Clin Proc 2008; 83: 870-9